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- Venous thromboembolism (VTE) is prevalent among 
cancer patients and is one of the leading causes of 
mortality in the cancer population1.
CC: 63yo F presents with hypoxia and L arm tingling.
- PMH: endometrial cancer mets to the brain, recent L 
parietal craniotomy for R focal motor seizures, PE 
and DVT 2 years ago with hemorrhagic conversion of 
brain metastases while on therapeutic Lovenox
- Meds: Lovenox 40mg SQ daily the last 2 years.
- Dx: saddle PE, occlusive thrombus left subclavian 
artery, right heart strain, b/l posterior tibial DVTs.
- Tx: therapeutic Lovenox. Decided to forgo hospice in 
favor of active treatment for her PE and her                             
metastatic endometrial cancer.
DISCUSSION
- Continuing anticoagulation in patients with cancer in 
hospice should be individualized.
- Anticoagulation may be appropriate to improve 
quality of life with the goal of symptom relief.
- A goals of care discussion should include an 
assessment of risk of bleeding which can have 
significant consequences of morbidity and mortality.
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Risks of bleeding Risks of thrombosis
Personal Characteristics:
Thrombocytopenia, 
bleeding disorder, renal or 
hepatic impairment
Obese, race (higher in 
African American), age, 
prolonged immobilization, 
renal or hepatic 
impairment, prior history
Cancer Dependent:
Mucosal tumors
Advanced stage or 
metastatic, especially 
stomach, pancreas, lung, 
lymphoma, Gyn, GU
Treatment Dependent:
Life threatening bleeding or 
active critical site bleed, 
Prior Hx of GI bleeding
Recent surgery, active 
chemotherapy, 
prothrombotic drugs (ex. 
Tamoxifen, antiandrogens, 
megestrol, thalidomide, 
lenalidomide)
•QOL, symptom management, anxiety regarding 
bleed vs. clot6
•Decision of the patient, not driven by prescriber’s 
personal views for the patient7Patient
Goal
•Table 1: Risk Factors
•Risk Calculators: POMPE-C, RIETE4, 
Khorana2, EPIPHANY5
Individual 
Risk/Benefit
•ASCO (8/2019): cancer+VTE= 
treat 6mo (sometimes longer 
in certain scenarios), LMWH 
preferred2
•NICE VTE ppx in palliative 
care if reversible acute 
pathology3
Guidelines
BACKGROUND
CASE
TABLE 1: RISK FACTORS 2,3
FIGURE 1: AN APPROACH TO DECISION MAKING
- Describe the current guidelines for CAT treatment.
- Assess risk factors for bleeding and thrombosis in 
cancer patients and risk/benefits of anticoagulation.
- Recognize the need for individualized 
anticoagulation plans in order to make informed 
decisions that may differ from the guidelines.
- Propose anticoagulation in hospice if it will achieve 
the goals of the patient.
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